J.-V. Malfuson

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

J.-V. Malfuson, A. Etienne, Pascal Turlure et al. · Haematologica · 2008 · 140 citations · Full text

Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy

Jordan Gauthier, Luca Castagna, Federico Garnier et al. · Bone Marrow Transplantation · 2017 · 36 citations

Lymphoid Neoplasia, Radiation Oncology, Hodgkin Lymphoma +11

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Raphaël Itzykson, Sylvain Thépot, Odile Beyne‐Rauzy et al. · Leukemia Research · 2011 · 15 citations

Hematological Malignancy, Bone Marrow Failure, Does Addition +7

Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse

J.-V. Malfuson, Johanna Konopacki, Cédric Thépenier et al. · Annals of Hematology · 2012 · 10 citations

Hematological Malignancy, Oncology, Gemtuzumab Ozogamicin +8